hVIVO (HVO) Share Price, News & Analysis

Company Overview

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Key Stats

• Today's Range: 5.90 to 6.20
• 50-Day Range: 5.88 to 7.75
• 52-Week Range: 4.31 to 11
• Volume: 578,700 shs
• Average Volume: 2.47 million shs
• Market Capitalization: £40.99 million
• P/E Ratio: N/A
• Dividend Yield: 2.68%
• Price Target: GBX 15
• Consensus Rating: Moderate Buy

hVIVO Stock Analysis - MarketRank™

hVIVO scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

hVIVO has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

hVIVO has a consensus price target of GBX 15, representing about 151.9% upside from its current price of GBX 5.96.

Amount of Analyst Coverage

hVIVO has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of hVIVO is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of hVIVO is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

hVIVO has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HVO.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

hVIVO pays a meaningful dividend of 2.68%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

hVIVO does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for hVIVO this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, hVIVO insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.95% of the stock of hVIVO is held by insiders.

Percentage Held by Institutions

12.66% of the stock of hVIVO is held by institutions.

Company Calendar

• Last Earnings: 9/15/2026
• Today: 10/04/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: LON:HVO
• Previous Symbol: LON:RVG
• CIK: N/A
• Web: hvivo.com
• Phone: +44-20-77561300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for hVIVO: GBX 15
• High Price Target: GBX 25
• Low Price Target: GBX 10
• Potential Upside/Downside: +151.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (1.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 3.84
• P/E Growth: N/A
• Net Income: £17.84 million
• Net Margins: -31.76%
• Pretax Margin: N/A
• Return on Equity: -35.13%
• Return on Assets: 11.97%

Debt

• Debt-to-Equity Ratio: 43.38
• Current Ratio: 1.21
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: £38.85 million
• Price / Sales: 1.06
• Cash Flow: GBX 1.21 per share
• Price / Cash Flow: 4.94
• Book Value: GBX 5.56 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 688,401,000
• Free Float: N/A
• Market Cap: £40.99 million
• Optionable: Not Optionable
• Beta: 1.69